WP
CLDI icon

Woodline Partners’s Calidi Biotherapeutics CLDI Stock Holding History

Woodline Partners’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-208
Closed -$4.2M – 615
2023
Q2 		$4.2M Hold
208
– – 0.05% 317
2023
Q1 		$4.11M Hold
208
– – 0.06% 319
2022
Q4 		$4.07M Hold
208
– – 0.05% 347
2022
Q3 		$3.94M Sell
208
-823
-80% -$15.8M 0.06% 342
2022
Q2 		$19.7M Hold
1,031
– – 0.3% 99
2022
Q1 		$19.6M Hold
1,031
– – 0.32% 95
2021
Q4 		$19.4M Buy
+1,031
New +$19.4M 0.28% 107

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $360M AUM 19.03% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Woodline Partners's CLDI Position: Q3 2023 in Review

Woodline Partners sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 208 shares — an estimated $4.2M sold.

Woodline Partners first reported a position in CLDI in Q4 2021 and held it in 7 quarters. The position peaked at $19.7M in Q2 2022. 10 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Woodline Partners reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Woodline Partners sold 208 Calidi Biotherapeutics shares in Q3 2023, an estimated $4.2M.
  • Woodline Partners first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 7 quarters.
  • Woodline Partners's Calidi Biotherapeutics position peaked at $19.7M in Q2 2022.
  • 10 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.